Poland· PL-100204024
Beriplex P/N 500
A coagulation factor ix, ii, vii and x in combination product containing prothrombinum multiplex humanum, registered in Poland by CSL Behring GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor ix, ii, vii and x in combination is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD01 (coagulation factor ix, ii, vii and x in combination), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor ix, ii, vii and x in combination · ATC B02BD01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Prothrombinum multiplex humanum
- Manufacturer
- CSL Behring GmbH
- Country
- Poland (PL)
- ATC code
- B02BD01
- ATC class
- Coagulation factor IX, II, VII and X in combination
- Defined daily dose
- 1.6 TSD, E
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990679188
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for coagulation factor ix, ii, vii and x in combination.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor ix, ii, vii and x in combination · interactions on record
3 records
- 2 severe
- 1 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor ix, ii, vii and x in combination in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b10d5ec6-7fff-4dd6-b77b-842225855996 GET /v1/drugs/b10d5ec6-7fff-4dd6-b77b-842225855996?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "500 j.m.",
"packaging": "05909990679188 ¦ Rp ¦ 47998\n1 fiol. proszku ¦ 1 system transferowy 20/20 z filtrem ¦ 1 fiol. 20 ml rozp.",
"substance": "Factor X coagulationis humanus 440-1200 j.m. (składnik zespołu ludzkiej protrombiny) + Białko S 260-520 j.m. (składnik zespołu ludzkiej protrombiny) + Białko C 300-900 j.m. (składnik zespołu ludzkiej protrombiny) + Factor VII coagulationis humanus 200-500 j.m. (składnik zespołu ludzkiej protrombiny) + Factor II coagulationis humanus 400-960 j.m. (składnik zespołu ludzkiej protrombiny) + Factor IX coagulationis humanus 400-620 j.m. (składnik zespołu ludzkiej protrombiny)",
"common_name": "Prothrombinum multiplex humanum",
"pl_product_id": "100204024",
"pozwolenie_nr": "15103",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about coagulation factor ix, ii, vii and x in combination.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.